Cargando…

Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory

OBJECTIVE: The prognostic value of cerebrospinal fluid neurofilament light chain, total tau, phosphorylated tau(181), and amyloid beta(1‐42) was examined in frontotemporal dementia subtypes. METHODS: We compared baseline biomarkers between 49 controls, 40 patients with behavioral variant frontotempo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ljubenkov, Peter A., Staffaroni, Adam M., Rojas, Julio C., Allen, Isabel E., Wang, Ping, Heuer, Hilary, Karydas, Anna, Kornak, John, Cobigo, Yann, Seeley, William W., Grinberg, Lea T., Spina, Salvatore, Fagan, Anne M., Jerome, Gina, Knopman, David, Boeve, Brad F., Dickerson, Bradford C., Kramer, Joel, Miller, Bruce, Boxer, Adam L., Rosen, Howard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186942/
https://www.ncbi.nlm.nih.gov/pubmed/30349860
http://dx.doi.org/10.1002/acn3.643
_version_ 1783362939267317760
author Ljubenkov, Peter A.
Staffaroni, Adam M.
Rojas, Julio C.
Allen, Isabel E.
Wang, Ping
Heuer, Hilary
Karydas, Anna
Kornak, John
Cobigo, Yann
Seeley, William W.
Grinberg, Lea T.
Spina, Salvatore
Fagan, Anne M.
Jerome, Gina
Knopman, David
Boeve, Brad F.
Dickerson, Bradford C.
Kramer, Joel
Miller, Bruce
Boxer, Adam L.
Rosen, Howard J.
author_facet Ljubenkov, Peter A.
Staffaroni, Adam M.
Rojas, Julio C.
Allen, Isabel E.
Wang, Ping
Heuer, Hilary
Karydas, Anna
Kornak, John
Cobigo, Yann
Seeley, William W.
Grinberg, Lea T.
Spina, Salvatore
Fagan, Anne M.
Jerome, Gina
Knopman, David
Boeve, Brad F.
Dickerson, Bradford C.
Kramer, Joel
Miller, Bruce
Boxer, Adam L.
Rosen, Howard J.
author_sort Ljubenkov, Peter A.
collection PubMed
description OBJECTIVE: The prognostic value of cerebrospinal fluid neurofilament light chain, total tau, phosphorylated tau(181), and amyloid beta(1‐42) was examined in frontotemporal dementia subtypes. METHODS: We compared baseline biomarkers between 49 controls, 40 patients with behavioral variant frontotemporal dementia, 24 with semantic variant primary progressive aphasia, and 26 with nonfluent variant primary progressive aphasia. Linear mixed effect models were used to assess the value of baseline biomarkers in predicting clinical and radiographic change in patient cohorts over multiple yearly follow up visits. RESULTS: Neurofilament light chain concentrations were lowest in controls. Elevated baseline neurofilament light chain predicted faster worsening in clinical severity, frontotemporal volume and frontotemporal fractional anisotropy in patients with behavioral variant frontotemporal dementia and nonfluent variant primary progressive aphasia. High total tau similarly predicted faster progression in nonfluent variant primary progressive aphasia. In behavioral variant frontotemporal dementia, higher phosphorylated tau(181) predicted faster clinical progression whereas lower amyloid beta(1‐42) predicted faster volumetric and fractional anisotropy reduction. Neurofilament light chain and phosphorylated tau(181) were of greater predictive value in patients with tau pathology as compared to TDP‐43 pathology. Baseline neurofilament light chain correlated with baseline clinical severity and frontotemporal volume in behavioral variant frontotemporal dementia. Baseline total tau correlated with baseline clinical severity in semantic variant primary progressive aphasia. INTERPRETATION: High cerebrospinal fluid neurofilament light chain predicts more aggressive disease in behavioral variant frontotemporal dementia and nonfluent variant primary progressive aphasia. Total tau, phosphorylated tau(181), and amyloid beta(1‐42) also predict some measures of disease aggressiveness in frontotemporal dementia.
format Online
Article
Text
id pubmed-6186942
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-61869422018-10-22 Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory Ljubenkov, Peter A. Staffaroni, Adam M. Rojas, Julio C. Allen, Isabel E. Wang, Ping Heuer, Hilary Karydas, Anna Kornak, John Cobigo, Yann Seeley, William W. Grinberg, Lea T. Spina, Salvatore Fagan, Anne M. Jerome, Gina Knopman, David Boeve, Brad F. Dickerson, Bradford C. Kramer, Joel Miller, Bruce Boxer, Adam L. Rosen, Howard J. Ann Clin Transl Neurol Research Articles OBJECTIVE: The prognostic value of cerebrospinal fluid neurofilament light chain, total tau, phosphorylated tau(181), and amyloid beta(1‐42) was examined in frontotemporal dementia subtypes. METHODS: We compared baseline biomarkers between 49 controls, 40 patients with behavioral variant frontotemporal dementia, 24 with semantic variant primary progressive aphasia, and 26 with nonfluent variant primary progressive aphasia. Linear mixed effect models were used to assess the value of baseline biomarkers in predicting clinical and radiographic change in patient cohorts over multiple yearly follow up visits. RESULTS: Neurofilament light chain concentrations were lowest in controls. Elevated baseline neurofilament light chain predicted faster worsening in clinical severity, frontotemporal volume and frontotemporal fractional anisotropy in patients with behavioral variant frontotemporal dementia and nonfluent variant primary progressive aphasia. High total tau similarly predicted faster progression in nonfluent variant primary progressive aphasia. In behavioral variant frontotemporal dementia, higher phosphorylated tau(181) predicted faster clinical progression whereas lower amyloid beta(1‐42) predicted faster volumetric and fractional anisotropy reduction. Neurofilament light chain and phosphorylated tau(181) were of greater predictive value in patients with tau pathology as compared to TDP‐43 pathology. Baseline neurofilament light chain correlated with baseline clinical severity and frontotemporal volume in behavioral variant frontotemporal dementia. Baseline total tau correlated with baseline clinical severity in semantic variant primary progressive aphasia. INTERPRETATION: High cerebrospinal fluid neurofilament light chain predicts more aggressive disease in behavioral variant frontotemporal dementia and nonfluent variant primary progressive aphasia. Total tau, phosphorylated tau(181), and amyloid beta(1‐42) also predict some measures of disease aggressiveness in frontotemporal dementia. John Wiley and Sons Inc. 2018-09-20 /pmc/articles/PMC6186942/ /pubmed/30349860 http://dx.doi.org/10.1002/acn3.643 Text en © 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Ljubenkov, Peter A.
Staffaroni, Adam M.
Rojas, Julio C.
Allen, Isabel E.
Wang, Ping
Heuer, Hilary
Karydas, Anna
Kornak, John
Cobigo, Yann
Seeley, William W.
Grinberg, Lea T.
Spina, Salvatore
Fagan, Anne M.
Jerome, Gina
Knopman, David
Boeve, Brad F.
Dickerson, Bradford C.
Kramer, Joel
Miller, Bruce
Boxer, Adam L.
Rosen, Howard J.
Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory
title Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory
title_full Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory
title_fullStr Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory
title_full_unstemmed Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory
title_short Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory
title_sort cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186942/
https://www.ncbi.nlm.nih.gov/pubmed/30349860
http://dx.doi.org/10.1002/acn3.643
work_keys_str_mv AT ljubenkovpetera cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory
AT staffaroniadamm cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory
AT rojasjulioc cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory
AT allenisabele cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory
AT wangping cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory
AT heuerhilary cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory
AT karydasanna cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory
AT kornakjohn cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory
AT cobigoyann cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory
AT seeleywilliamw cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory
AT grinbergleat cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory
AT spinasalvatore cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory
AT faganannem cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory
AT jeromegina cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory
AT knopmandavid cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory
AT boevebradf cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory
AT dickersonbradfordc cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory
AT kramerjoel cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory
AT millerbruce cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory
AT boxeradaml cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory
AT rosenhowardj cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory